Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825698 | 0.95 | PTGES (0.44) | PTGESKIF11KCNH2PDPK1SERPINE1 | |
| SCHEMBL20826117 | 0.91 | KCNH2 (0.39) | PTGESKIF11KCNH2SERPINE1CASR | |
| SCHEMBL20826223 | 0.91 | KCNH2 (0.39) | PTGESKIF11KCNH2SERPINE1CASR | |
| SCHEMBL20850481 | 0.89 | PTGES (0.45) | PTGESKIF11KCNH2SERPINE1NR1H4 | |
| SCHEMBL20826233 | 0.86 | PTGES (0.42) | PTGESKIF11KCNH2SERPINE1CASR | |
| SCHEMBL20825696 | 0.86 | PTGES (0.42) | PTGESKIF11KCNH2SERPINE1CASR | |
| SCHEMBL21944398 | 0.84 | PTGES (0.35) | PTGESKCNH2CASRNPC1RAB9A | |
| SCHEMBL28805106 | 0.83 | PTGES (0.35) | PTGESKIF11KCNH2PIK3CACA12 | |
| SCHEMBL19735301 | 0.83 | PTGES (0.44) | PTGESKIF11SERPINE1NR1H4PPARG | |
| SCHEMBL16520483 | 0.82 | PTGES (0.39) | PTGESSERPINE1NR1H4OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793074-B2 | Organic compound and photoelectric conversion element | CANON KABUSHIKI KAISHA (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11793074-B2 | Organic compound and photoelectric conversion element | CANON KABUSHIKI KAISHA (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20210057653-A1 | ORGANIC COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT | CANON KK (JP) | 2021-02-25 | — | — | US | disclosed |
| US-10868260-B2 | Organic compound and photoelectric conversion element | CANON KABUSHIKI KAISHA (JP) | 2020-12-15 | — | — | US | disclosed |
| US-20190088885-A1 | ORGANIC COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793074-B2 | Organic compound and photoelectric conversion element | CRY1, CYP1A1, CCNE2 | PTGES 3027/4885KIF11 3445/4885KCNH2 83/4885 |
| US-20210057653-A1 | ORGANIC COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT | CRY1, CYP1A1, CCNE2 | PTGES 3027/4885KIF11 3445/4885KCNH2 83/4885 |
| US-10868260-B2 | Organic compound and photoelectric conversion element | CRY1, CYP1A1, CCNE2 | PTGES 3027/4885KIF11 3445/4885KCNH2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.